The present meta-analysis highlights MPO as a promising biomarker of cancer-therapy-related cardiotoxicity, whereas the available evidence does not yet consistently support a beneficial role for galectin-3, potentially due to significant heterogeneity. The gene discussed is LGALS3; the disease is cancer.